Eli Lilly and Company and its wholly owned subsidiary Avid Radiopharmaceuticals Inc., have announced that Amyvid in available to imaging centres in markets surrounding 16 manufacturing sites located in Atlanta; Charlotte, Chicago, Colton, Columbus, Dallas, Fort Lauderdale, Hartford, Houston, Jacksonville, North Wales, Orlando, Palo Alto, Phoenix, Seattle, and St. Louis.
Because Amyvid loses over half of its radioactivity every two hours, it must be distributed directly to imaging centres from the specialized radiopharmacies where it is produced. Patients should speak to their health care provider to determine if Amyvid is an appropriate option for them and to determine if it is available in their area.
“In the roughly two months since the approval of Amyvid, we have been working closely with imaging centres to ensure they are prepared to provide Amyvid to their customers,” said Daniel Skovronsky, MD, PhD, president and CEO of Avid, and global brand development leader for Amyvid at Lilly. “We are committed to providing Amyvid to physicians, patients and their families in as many areas as possible as quickly as we can.”
To coincide with the availability of Amyvid, Lilly is also announcing the launch of their reader training programme. An online training programme, developed by Lilly and Avid, is now available at AmyvidTraining.com. The companies also collaborated with the American College of Radiology to present a live, in-person training programme, which will be launched on June 11, 2012, in Miami. These reader training programmes were developed to provide training for radiologists and nuclear medicine physicians who will be responsible for reading Amyvid scans. Amyvid images should be interpreted only by readers who have successfully completed the Amyvid reader training. Errors may occur in the estimation of plaque density during image interpretation.
Amyvid is the first-and-only radioactive diagnostic agent approved by the US Food and Drug Administration (FDA) for PET imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline.
Amyvid works by binding to amyloid plaques, one of the necessary pathological features of Alzheimer's disease, and is detected using PET scan images of the brain. A negative Amyvid scan indicates sparse to no amyloid plaques are currently present, which is inconsistent with a neuropathological diagnosis of Alzheimer's disease and reduces the likelihood that a patient's cognitive impairment is due to Alzheimer's disease. A positive Amyvid scan indicates moderate to frequent amyloid plaques are present; this amount of amyloid plaque is present in patients with Alzheimer's disease, but may also be present in patients with other types of neurologic conditions and in older people with normal cognition.
It's important to note that Amyvid is an adjunct to other diagnostic evaluations. A positive Amyvid scan does not establish a diagnosis of Alzheimer's disease or other cognitive disorder. Additionally, the safety and effectiveness of Amyvid have not been established for predicting development of dementia or other neurologic condition, or monitoring responses to therapies.
Amyvid is a radioactive diagnostic agent, tagged with a radioisotope called fluorine-18. Once Amyvid is injected into a vein, it travels through the bloodstream and into the brain, binding to amyloid plaques. Amyvid produces a positron signal, which is detected by a PET scanner and used to create a brain image. A radiologist, who should have successfully completed Amyvid reader training, then interprets the image to evaluate for the presence or absence of significant amyloid plaques (i.e., moderate to frequent levels of neuritic plaques) in the brain. This information is reported back to the referring physician, who then determines the next steps in the evaluation and management of the patient.
Amyvid is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline.
A negative Amyvid scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Amyvid scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Amyvid is an adjunct to other diagnostic evaluations.
A positive Amyvid scan does not establish a diagnosis of AD or other cognitive disorder. Additionally, the safety and effectiveness of Amyvid have not been established for predicting development of dementia or other neurologic condition, or monitoring responses to therapies.
Amyvid for intravenous use is supplied in 10 mL, 30 mL, or 50 mL multidose vials containing 500-1900 MBq/mL Florbetapir F 18.
Errors may occur in the Amyvid estimation of brain neuritic plaque density during image interpretation.
Image interpretation should be performed independently of the patient's clinical information. The use of clinical information in the interpretation of Amyvid images has not been evaluated and may lead to errors. Other errors may be due to extensive brain atrophy that limits the ability to distinguish gray and white matter on the Amyvid scan as well as motion artifacts that distort the image.
Amyvid scan results are indicative of the brain neuritic amyloid plaque content only at the time of image acquisition and a negative scan result does not preclude the development of brain amyloid in the future.
Amyvid, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure.
The most common adverse reactions reported in clinical trials were headache (1.8 per cent), musculoskeletal pain (0.8 per cent), fatigue (0.6 per cent), nausea (0.6 per cent), anxiety (0.4 per cent), back pain (0.4 per cent), blood pressure increased (0.4 per cent), claustrophobia (0.4 per cent), feeling cold (0.4 per cent), insomnia (0.4 per cent), neck pain (0.4 per cent).
Pharmacodynamic drug-drug interaction studies have not been performed in patients to establish the extent, if any, to which concomitant medications may alter Amyvid image results.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations.